Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly - MarketWatch
1. Zepbound approved to treat obstructive sleep apnea in patients with obesity. 2. Medicare drug plans will now cover Eli Lilly's Zepbound, boosting sales. 3. First FDA-approved treatment for 20 million Americans with this disorder.